Impact of Switching from Double-Blind Placebo or Entacapone to Open-Label Opicapone in Updrs-Ii and Iii Scores in the Open-Label 1-Year Extension Bipark-I Study
AuthID
P-00Q-VZ7
P-00Q-VZ7
© 2024 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service